THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC
LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT
VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL
BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.
15 October
2024
Graft Polymer (UK) Plc
(the "Company")
Research agreement with the
University of Nottingham
Graft Polymer (UK) Plc (LON: GPL)
(the "Company"), an innovative biotechnology company co-developing
therapeutics for mental health disorders, announces that its
partner, Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF)
("Awakn"), has entered a research agreement with the University of
Nottingham. The research will be conducted in vivo and will
evaluate the potential of the Company and Awakn's aminoindane
new chemical entity ("NCE") co-lead series to enhance social
cognition and pro-social behaviors, a critical step in developing a
new class of medicines for treating trauma-related disorders such
as Post-Traumatic Stress Disorder ("PTSD").
The research will be led by Dr.
Madeleine King, Assistant Professor in the Faculty of Medicine
& Health Sciences at the University of Nottingham, which is
recognised globally for its cutting-edge neuroscience research. Dr.
King brings over 20 years of experience in behavioral neuroscience,
focusing on psychiatric disorder research. The research will employ
the Social Transmission of Food Preferences ("STFP") test in rodent
models and is expected to run over two months, with results due by
the end of 2024.
This in vivo research represents a
significant step in the Company's NCE programme, which is being
developed under a collaboration agreement with Awakn. The programme
is focused on developing next-generation therapeutics for mental
health disorders, including PTSD, a condition affecting over 13
million adults in the U.S. and 20 million across the U.S., UK, and
Europe.
Anthony Tennyson, CEO of Graft
Polymer, commented: "This is a
significant step forward in our joint programme with Awakn. The in
vivo testing at the University of Nottingham will be pivotal in
assessing the therapeutic potential of our novel aminoindane
compounds, bringing us closer to addressing the unmet needs in
trauma-related mental health disorders."
Dr Madeline King, from the School of
Life Sciences at the University of Nottingham said: "I'm delighted that Awakn Life Sciences have
chosen to collaborate with the University of Nottingham. I'm
excited to be involved in this research, which has real potential
to improve patient health."
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk
Allenby Capital (Broker) +44 (0)
20 3328 5656
Nick Naylor /
Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an
innovative biotechnology company focused on developing intellectual property relating to the treatment of
mental health and substance use disorders, and the co-development
of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on
trauma-related mental health disorders, such as PTSD, which affects
approximately 13 million adults in the U.S. and 20 million in US,
UK, and key EU markets.
For more information, please visit
www.graftpolymer.co.uk.